Mary Quinn

1.1k total citations
26 papers, 804 citations indexed

About

Mary Quinn is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mary Quinn has authored 26 papers receiving a total of 804 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mary Quinn's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer therapeutics and mechanisms (5 papers). Mary Quinn is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (10 papers) and Cancer therapeutics and mechanisms (5 papers). Mary Quinn collaborates with scholars based in United States, Malaysia and Ukraine. Mary Quinn's co-authors include Jean L. Grem, Rebecca R. Thomas, Richard H. Wilson, Mary Kay Floeter, Tanya Lehky, Barbara Schüler, Nancy Harold, Gregory D. Leonard, Suzanne Fioravanti and M. A. Wright and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Mary Quinn

25 papers receiving 786 citations

Peers

Mary Quinn

ONCOL

DERMA

PFM

PRM

G. Catalano Italy

Gaofeng Zheng China

Kunwu Yu China

Quan Lin China

Juan Moreno‐Rubio Spain

Shuichiro Hamano Japan

Shinya Sakurai Japan

Ifeyinwa E. Obiorah United States

Sebastian Walpen Switzerland

Yucheng Zhong China

G. Catalano Italy

Mary Quinn

450 ×0.8

ONCOL

39 ×0.2

DERMA

181 ×1.1

129 ×1.4

PFM

206 ×2.3

PRM

Citations per year, relative to Mary Quinn Mary Quinn (= 1×) peers G. Catalano

Countries citing papers authored by Mary Quinn

Since Specialization

Citations

This map shows the geographic impact of Mary Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Quinn more than expected).

Fields of papers citing papers by Mary Quinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Quinn. The network helps show where Mary Quinn may publish in the future.

Co-authorship network of co-authors of Mary Quinn

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Quinn. A scholar is included among the top collaborators of Mary Quinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Quinn. Mary Quinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reid, Tony, Bryan Oronsky, Scott Caroen, et al.. (2023). Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). Frontiers in Immunology. 14. 1104753–1104753. 14 indexed citations

Oronsky, Bryan, Tony R. Reid, Christopher Larson, et al.. (2019). REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer. Future Oncology. 15(30). 3427–3433. 47 indexed citations

Coyne, Geraldine O’Sullivan, Shivaani Kummar, Naoko Takebe, et al.. (2018). Abstract B079: Single agent AZD 1775, a Wee1 inhibitor, shows activity in BRCA deficient patients. Molecular Cancer Therapeutics. 17(1_Supplement). B079–B079. 1 indexed citations

Brzezniak, Christina, Mary Quinn, Bryan Oronsky, et al.. (2017). P2.06-031 QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets. Journal of Thoracic Oncology. 12(1). S1090–S1091. 1 indexed citations

Carter, Corey A., Paul Peterson, Mary Quinn, et al.. (2016). Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Reports in Oncology. 9(1). 164–170. 12 indexed citations

Sausville, E. A., P. LoRusso, Mary Quinn, et al.. (2007). A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2577–2577. 14 indexed citations

Leonard, Gregory D., M. A. Wright, Mary Quinn, et al.. (2005). Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 5(1). 116–116. 135 indexed citations

Leonard, Gregory D., Michael Wagner, Mary Quinn, & Jean L. Grem. (2004). Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy. Anti-Cancer Drugs. 15(7). 733–735. 9 indexed citations

Thomas, Rebecca R., Mary Quinn, Barbara Schüler, & Jean L. Grem. (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 97(9). 2301–2307. 91 indexed citations

10.

Grem, Jean L., Mary Quinn, Bruce Keith, et al.. (2003). A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin. Cancer Chemotherapy and Pharmacology. 52(6). 487–496. 4 indexed citations

11.

Quinn, Mary, et al.. (2003). A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer Chemotherapy and Pharmacology. 52(4). 333–338. 8 indexed citations

12.

Saif, Muhammad Wasif, et al.. (2003). Cardiac Toxicity Associated with Capecitabine Therapy. Acta Oncologica. 42(4). 342–344. 14 indexed citations

13.

Harold, Nancy, Muhammad Wasif Saif, Barbara Schüler, et al.. (2003). Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemotherapy and Pharmacology. 52(1). 79–85. 13 indexed citations

14.

Keith, Bruce, Suzanne Zentko, Nancy Harold, et al.. (2002). Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.. PubMed. 8(5). 1045–50. 4 indexed citations

15.

Wilson, Richard H., Tanya Lehky, Rebecca R. Thomas, et al.. (2002). Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability. Journal of Clinical Oncology. 20(7). 1767–1774. 259 indexed citations

16.

Grem, Jean L., Mary Quinn, Chris H. Takimoto, et al.. (2001). Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemotherapy and Pharmacology. 47(2). 117–125. 11 indexed citations

17.

Grem, Jean L., Nancy Harold, Jeremy Shapiro, et al.. (2000). Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors. Journal of Clinical Oncology. 18(23). 3952–3963. 20 indexed citations

18.

Quinn, Mary, et al.. (2000). The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. Oncology Issues. 15(6). 23–27. 4 indexed citations

19.

Shapiro, Jeremy, Nancy Harold, J. Michael Hamilton, et al.. (1999). A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.. PubMed. 5(9). 2399–408. 4 indexed citations

20.

Grem, Jean L., Nanette McAtee, Richard F. Murphy, et al.. (1997). A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.. PubMed. 3(7). 1125–34. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact